Clozapine Use Linked to Higher SARS-CoV-2 Infection Risk in Severe Mental Disorders

This meta-analysis, systematic review, and retrospective cohort study investigated the association between clozapine use and SARS-CoV-2 infection risk and COVID-19 severity in outpatients with severe mental disorders. The analysis included 155,945 patients, though the specific setting (e.g., geographic location, healthcare system) was not reported. The intervention/exposure was clozapine use, compared to non-users of clozapine (which may include users of other antipsychotics or no antipsychotic medication).

The primary outcome was SARS-CoV-2 infection rate and COVID-19 severity. The main results showed that clozapine users had a higher rate of SARS-CoV-2 infection compared to non-users, with an absolute rate of 18% versus 10% (odds ratio [OR] 1.53, 95% confidence interval [CI]: 1.02-2.30, p = 0.044). This indicates a statistically significant increased risk of infection associated with clozapine use. Additionally, COVID-19 severity was reported to be increased in clozapine users compared to non-users, but no specific effect size, absolute numbers, or confidence intervals were provided for this outcome.

Secondary outcomes were not reported in the available data. Safety and tolerability findings, including adverse events, serious adverse events, discontinuations, and overall tolerability, were also not reported. The study did not provide information on follow-up duration, funding sources, or conflicts of interest.

A key limitation noted is high heterogeneity (I² = 91.2%), which suggests substantial variation in effects across the included studies. This high heterogeneity reduces the reliability of the pooled estimates and indicates that the true effect may differ depending on study characteristics. The authors caution that the findings represent an association, not causation, and that further research is needed to clarify the relationship.

Compared to prior studies, this meta-analysis adds to the evidence base by pooling data from multiple sources, but the high heterogeneity limits direct comparison with landmark trials. Previous research has suggested that clozapine may have immunomodulatory effects, which could theoretically increase susceptibility to infections, but this remains speculative.

Methodological limitations include the lack of reported details on study design, setting, and patient characteristics, which may introduce bias. The retrospective nature of the included cohort studies also raises concerns about confounding by indication (e.g., patients on clozapine may have more severe mental illness or other comorbidities that independently increase infection risk).

Clinically, these findings suggest that clinicians should be vigilant about infection risk in patients with severe mental disorders who are prescribed clozapine, particularly during the COVID-19 pandemic. However, given the observational nature and high heterogeneity, these results should not prompt changes in clozapine prescribing without further evidence. The benefits of clozapine for treatment-resistant schizophrenia must be weighed against potential risks.

Unanswered questions include whether the increased infection risk is specific to clozapine or applies to other antipsychotics, the mechanisms underlying the association, and whether interventions such as vaccination or prophylactic measures can mitigate risk. Future studies should aim to control for confounders and provide more granular data on COVID-19 severity and outcomes.